Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Evaluate the Efficacy and Safety of Octagam 10% in Idiopathic Thrombocytopenic Purpura in Adults

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosis of Idiopathic Thrombocytopenic Purpura (ITP) according to standard criteria.~* Platelet count ≤ 20 x 10\^9/L.~Key Exclusion Criteria:~* Chronic refractory ITP patients.~* Thrombocytopenia secondary to other diseases, or drug related thrombocytopenia.~* Administration of IGIV, anti-D, or other platelet enhancing drugs within 30 days before enrollment.~* Administration of thrombocyte concentrates within 72 hours before baseline.~* Experimental treatment (eg, rituximab) within 3 months before enrollment.~* Prophylactic preoperative treatment for elective splenectomy.~* Severe liver or kidney disease.~* Pregnant or nursing female.~* History of hypersensitivity to blood or plasma derived products.~* Emergency operation.~* Live viral vaccination within the last month prior to study entry.~* Known IgA deficiency and antibodies against IgA.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Octagam 10% 1 g/kg/day (Type: EXPERIMENTAL): Participants received Octagam 10% (human normal immunoglobulin) 1 g/kg intravenously once a day for 2 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).